Nehme El-Hachem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nehme El-Hachem has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Haibe-Kains
Princess Margaret Cancer Center, University Health Network
22 shared publications - Alexis Vallée
Sainte-Justine University Hospital and Research Center, Montreal, Canada
10 shared publications - Arnau Ballestero Vidal
Sainte-Justine University Hospital and Research Center, Montreal, Canada
10 shared publications - Benoîte Bourdin
Sainte-Justine University Hospital and Research Center, Montreal, Canada
10 shared publications - Clémence Ruisseaux
Sainte-Justine University Hospital and Research Center, Montreal, Canada
10 shared publications - Edward O. Kwarteng
Sainte-Justine University Hospital and Research Center, Montreal, Canada
10 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
IL2Rβ deficiency favors progenitor TEX states during chronic LCMV infection
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
IL2Rβ deficiency favors progenitor TEX states during chronic LCMV infection
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
T-cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T-cell states remains incompletely defined. Using an in vitro model of repetitive T-cell receptor stimulation, we found that high-dose interleukin 2 (IL2) or IL15 promoted exhausted CD8+ T-cell (TEX) differentiation, with increased inhibitory receptor expression and loss of stem-like features. During chronic lymphocytic choriomeningitis virus clone 13 infection, high IL2Rβ expression marked virus-specific CD8+ T cells with features of terminally exhausted T cells, whereas IL2Rβ deficiency favored progenitor-like populations. In TEX, IL2 and IL15 preferentially induced STAT5 phosphorylation over other signaling pathways. Genetic disruption of STAT5 similarly supported progenitor subsets, implicating STAT5 in the progression toward more differentiated TEX states under chronic stimulation. We therefore asked whether transient STAT5 attenuation during in vitro T-cell expansion could bias differentiation toward progenitor-like populations without compromising functional competence. Transient JAK3 or STAT5 inhibition enriched TCF1+Ly108+ progenitor–like cells while preserving cytokine production and degranulation capacity. Following transfer into tumor-bearing mice, cells expanded under STAT5-inhibited conditions mediated superior tumor control and prolonged survival. Likewise, transient STAT5 inhibition preserved memory–progenitor phenotypes in human CD22 chimeric antigen receptor T cells without impairing cytotoxicity. RNA sequencing of STAT5 inhibitor–expanded CD8+ T cells confirmed reinforced stem-like transcriptional programs and reduced enrichment of effector and exhausted signatures. Together, these findings identify the IL2Rβ–STAT5 axis as a regulator of CD8+ T-cell differentiation and support transient STAT5 modulation during ex vivo expansion to improve therapeutic T-cell products.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
T-cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T-cell states remains incompletely defined. Using an in vitro model of repetitive T-cell receptor stimulation, we found that high-dose interleukin 2 (IL2) or IL15 promoted exhausted CD8+ T-cell (TEX) differentiation, with increased inhibitory receptor expression and loss of stem-like features. During chronic lymphocytic choriomeningitis virus clone 13 infection, high IL2Rβ expression marked virus-specific CD8+ T cells with features of terminally exhausted T cells, whereas IL2Rβ deficiency favored progenitor-like populations. In TEX, IL2 and IL15 preferentially induced STAT5 phosphorylation over other signaling pathways. Genetic disruption of STAT5 similarly supported progenitor subsets, implicating STAT5 in the progression toward more differentiated TEX states under chronic stimulation. We therefore asked whether transient STAT5 attenuation during in vitro T-cell expansion could bias differentiation toward progenitor-like populations without compromising functional competence. Transient JAK3 or STAT5 inhibition enriched TCF1+Ly108+ progenitor–like cells while preserving cytokine production and degranulation capacity. Following transfer into tumor-bearing mice, cells expanded under STAT5-inhibited conditions mediated superior tumor control and prolonged survival. Likewise, transient STAT5 inhibition preserved memory–progenitor phenotypes in human CD22 chimeric antigen receptor T cells without impairing cytotoxicity. RNA sequencing of STAT5 inhibitor–expanded CD8+ T cells confirmed reinforced stem-like transcriptional programs and reduced enrichment of effector and exhausted signatures. Together, these findings identify the IL2Rβ–STAT5 axis as a regulator of CD8+ T-cell differentiation and support transient STAT5 modulation during ex vivo expansion to improve therapeutic T-cell products.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
JAK inhibition favors stem-like progenitor differentiation in vitro
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
JAK inhibition favors stem-like progenitor differentiation in vitro
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
STAT5 inhibition enhances stem-like features in CD8+ T cells stimulated
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
STAT5 inhibition enhances stem-like features in CD8+ T cells stimulated
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1587-1603
In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
T-cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T-cell states remains incompletely defined. Using an in vitro model of repetitive T-cell receptor stimulation, we found that high-dose interleukin 2 (IL2) or IL15 promoted exhausted CD8+ T-cell (TEX) differentiation, with increased inhibitory receptor expression and loss of stem-like features. During chronic lymphocytic choriomeningitis virus clone 13 infection, high IL2Rβ expression marked virus-specific CD8+ T cells with features of terminally exhausted T cells, whereas IL2Rβ deficiency favored progenitor-like populations. In TEX, IL2 and IL15 preferentially induced STAT5 phosphorylation over other signaling pathways. Genetic disruption of STAT5 similarly supported progenitor subsets, implicating STAT5 in the progression toward more differentiated TEX states under chronic stimulation. We therefore asked whether transient STAT5 attenuation during in vitro T-cell expansion could bias differentiation toward progenitor-like populations without compromising functional competence. Transient JAK3 or STAT5 inhibition enriched TCF1+Ly108+ progenitor–like cells while preserving cytokine production and degranulation capacity. Following transfer into tumor-bearing mice, cells expanded under STAT5-inhibited conditions mediated superior tumor control and prolonged survival. Likewise, transient STAT5 inhibition preserved memory–progenitor phenotypes in human CD22 chimeric antigen receptor T cells without impairing cytotoxicity. RNA sequencing of STAT5 inhibitor–expanded CD8+ T cells confirmed reinforced stem-like transcriptional programs and reduced enrichment of effector and exhausted signatures. Together, these findings identify the IL2Rβ–STAT5 axis as a regulator of CD8+ T-cell differentiation and support transient STAT5 modulation during ex vivo expansion to improve therapeutic T-cell products.
- 22 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1587-1603
Open AccessIn Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy
T-cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T-cell states remains incompletely defined. Using an in vitro model of repetitive T-cell receptor stimulation, we found that high-dose interleukin 2 (IL2) or IL15 promoted exhausted CD8+ T-cell (TEX) differentiation, with increased inhibitory receptor expression and loss of stem-like features. During chronic lymphocytic choriomeningitis virus clone 13 infection, high IL2Rβ expression marked virus-specific CD8+ T cells with features of terminally exhausted T cells, whereas IL2Rβ deficiency favored progenitor-like populations. In TEX, IL2 and IL15 preferentially induced STAT5 phosphorylation over other signaling pathways. Genetic disruption of STAT5 similarly supported progenitor subsets, implicating STAT5 in the progression toward more differentiated TEX states under chronic stimulation. We therefore asked whether transient STAT5 attenuation during in vitro T-cell expansion could bias differentiation toward progenitor-like populations without compromising functional competence. Transient JAK3 or STAT5 inhibition enriched TCF1+Ly108+ progenitor–like cells while preserving cytokine production and degranulation capacity. Following transfer into tumor-bearing mice, cells expanded under STAT5-inhibited conditions mediated superior tumor control and prolonged survival. Likewise, transient STAT5 inhibition preserved memory–progenitor phenotypes in human CD22 chimeric antigen receptor T cells without impairing cytotoxicity. RNA sequencing of STAT5 inhibitor–expanded CD8+ T cells confirmed reinforced stem-like transcriptional programs and reduced enrichment of effector and exhausted signatures. Together, these findings identify the IL2Rβ–STAT5 axis as a regulator of CD8+ T-cell differentiation and support transient STAT5 modulation during ex vivo expansion to improve therapeutic T-cell products.